Cannabichromene (CBC) is a non-intoxicating compound found naturally in the cannabis plant. First isolated in 1966 by Raphael Mechoulam and Yechiel Gaoni, the same researchers who identified THC and CBD, CBC is one of the major cannabinoids produced by cannabis. It won’t get you high, but it interacts with your body in ways that are distinct from its more famous relatives.
How CBC Differs From THC and CBD
All three compounds start from the same chemical precursor inside the cannabis plant, but enzymes steer them down different paths. THC is the one that produces a high. CBD has become widely known for its calming and anti-inflammatory reputation. CBC takes a third route entirely, and while it’s less abundant in most modern cannabis strains, it’s far from inactive.
The key distinction is how CBC interacts with your body’s receptors. Lab studies show CBC is a selective agonist of the CB2 receptor, the cannabinoid receptor concentrated in immune cells and peripheral tissues rather than the brain. In cell-based experiments, CBC actually showed higher efficacy at CB2 than THC did. It doesn’t meaningfully activate CB1, the receptor responsible for the psychoactive effects of cannabis. This selectivity is a big part of why CBC doesn’t produce intoxication.
How CBC Works in the Body
Beyond CB2, CBC has a particularly strong effect on a family of receptors called TRP channels. These are sensory receptors found throughout your body that detect things like pain, temperature, and irritation. CBC is the most potent cannabinoid activator of TRPA1, a channel involved in pain and inflammation signaling, with activity at extremely low concentrations. It also activates TRPV1, the same receptor that responds to capsaicin in hot peppers.
This unusual receptor profile means CBC works through pathways that are partly independent of the classic cannabinoid system. In several inflammation studies, blocking CB1 and CB2 receptors didn’t eliminate CBC’s effects, suggesting it has mechanisms that scientists haven’t fully mapped yet. That independence from the traditional cannabinoid receptors is one reason researchers find it interesting as a potential therapeutic compound on its own terms.
Anti-Inflammatory Effects
Inflammation is the area where CBC has the most consistent evidence, though nearly all of it comes from lab and animal studies rather than human trials. When immune cells are exposed to bacterial toxins in a dish, CBC reduces their production of several key inflammatory signals, including molecules that drive swelling, redness, and tissue damage. Multiple animal studies have also found that CBC reduces swelling when injected alongside an inflammatory agent in the paws of mice and rats.
In a mouse model of acute respiratory distress syndrome, inhaled CBC reduced inflammatory markers through TRPA1 and TRPV1 pathways. CBC has also been shown to calm inflammation-driven overactivity in the gut, a finding relevant to conditions like inflammatory bowel disease. Notably, many of these anti-inflammatory effects appear to work through a cell signaling cascade called the MAPK pathway rather than through the cannabinoid receptors alone.
Pain Relief
CBC’s pain-relieving properties seem to rely on a combination of receptors working together. Blocking experiments in animal studies show that its ability to reduce pain depends on at least three different targets: CB1, TRPA1, and the adenosine A1 receptor. Adenosine is a natural chemical your body uses to dampen pain signals, and CBC appears to tap into that system alongside its TRP channel activity. This multi-target approach is different from how THC reduces pain (primarily through CB1) and could explain why some researchers see CBC as a complement to other cannabinoids rather than a replacement.
Effects on Mood
Animal studies using standard behavioral tests for depression have found that CBC produces antidepressant-like effects. In the forced swim test, a common screening tool for antidepressant activity, CBC significantly reduced immobility at a dose of 20 mg/kg. In the tail suspension test, another standard model, CBC showed a dose-dependent reduction in immobility that was significant at 40 and 80 mg/kg doses. These are rodent models, and they don’t translate directly to human depression, but the consistency across two different tests is noteworthy. Importantly, these effects occurred without the psychoactive properties that come with THC.
Brain Cell Support
One of the more surprising findings about CBC involves neural stem and progenitor cells, the cells in the brain that can develop into new neurons or support cells. In a 2013 study, researchers tested CBC alongside CBD and CBG on mouse brain stem cells and found that CBC had a positive effect on their survival during the differentiation process. CBC appeared to keep these precursor cells viable while preventing them from turning into astrocytes, a type of support cell that, when overproduced, can contribute to neuroinflammation. The effect seemed to involve increased energy metabolism within the cells, measured by higher levels of ATP. This is early-stage lab research, but it hints at a role for CBC in brain health that other cannabinoids don’t share.
Skin and Acne
CBC has shown promise in lab studies on human sebocytes, the cells that produce the oily substance (sebum) in your skin. At moderate concentrations, CBC suppressed baseline sebum production and significantly reduced the excess oil production triggered by arachidonic acid, a fatty acid that ramps up during acne flare-ups. At very high concentrations (50 micromolar and above), CBC triggered cell death in sebocytes, so dosing matters. Researchers who tested several cannabinoids side by side concluded that CBC, along with THCV and CBDV, showed the most potential as anti-acne agents, while other cannabinoids like CBG actually increased oil production and might be better suited for dry skin.
Why CBC Appears in Full-Spectrum Products
You’ll often see CBC mentioned in the context of full-spectrum cannabis or hemp extracts. The idea is that cannabinoids may work better together than in isolation, a concept sometimes called the entourage effect. CBC’s unique receptor profile supports this idea in principle: because it works through different pathways than THC or CBD, it could fill in gaps that those compounds miss. Its strong TRPA1 activity, its selective CB2 activation, and its adenosine-related pain relief all represent mechanisms that THC and CBD don’t fully cover on their own.
That said, most commercial cannabis strains contain relatively small amounts of CBC compared to THC or CBD. Hemp-derived CBC isolates and CBC-enriched oils have started appearing on the market, but the research supporting specific doses for humans is still limited. The animal and cell studies are promising across multiple areas, from inflammation to mood to skin health, but human clinical trials remain the missing piece.